Literature DB >> 17916800

Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.

Suzanne L Tomchuck1, Kevin J Zwezdaryk, Seth B Coffelt, Ruth S Waterman, Elizabeth S Danka, Aline B Scandurro.   

Abstract

Adult human bone marrow-derived mesenchymal stem cells (hMSCs) are under study as therapeutic delivery agents that assist in the repair of damaged tissues. To achieve the desired clinical outcomes for this strategy requires a better understanding of the mechanisms that drive the recruitment, migration, and engraftment of hMSCs to the targeted tissues. It is known that hMSCs are recruited to sites of stress or inflammation to fulfill their repair function. It is recognized that toll-like receptors (TLRs) mediate stress responses of other bone marrow-derived cells. This study explored the role of TLRs in mediating stress responses of hMSCs. Accordingly, the presence of TLRs in hMSCs was initially established by reverse transcription-polymerase chain reaction assays. Flow cytometry and fluorescence immunocytochemical analyses confirmed these findings. The stimulation of hMSCs with TLR agonists led to the activation of downstream signaling pathways, including nuclear factor kappaB, AKT, and MAPK. Consequently, activation of these pathways triggered the induction and secretion of cytokines, chemokines, and related TLR gene products as established from cDNA array, immunoassay, and cytokine antibody array analyses. Interestingly, the unique patterns of affected genes, cytokines, and chemokines measured identify these receptors as critical players in the clinically established immunomodulation observed for hMSCs. Lastly, hMSC migration was promoted by TLR ligand exposure as demonstrated by transwell migration assays. Conversely, disruption of TLRs by neutralizing TLR antibodies compromised hMSC migration. This study defines a novel TLR-driven stress and immune modulating response for hMSCs that is critical to consider in the design of stem cell-based therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916800      PMCID: PMC2757778          DOI: 10.1634/stemcells.2007-0563

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  25 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

Review 2.  Toll-like receptors in health and disease: complex questions remain.

Authors:  Ian Sabroe; Robert C Read; Moira K B Whyte; David H Dockrell; Stefanie N Vogel; Steven K Dower
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

3.  NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.

Authors:  Gregory Helbig; Kent W Christopherson; Poornima Bhat-Nakshatri; Suresh Kumar; Hiromitsu Kishimoto; Kathy D Miller; Hal E Broxmeyer; Harikrishna Nakshatri
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

4.  Role of toll-like receptors on human adipose-derived stromal cells.

Authors:  Hyun Hwa Cho; Yong Chan Bae; Jin Sup Jung
Journal:  Stem Cells       Date:  2006-08-10       Impact factor: 6.277

5.  Inhibition of the stem cell factor-induced migration of mast cells by dexamethasone.

Authors:  Hyun-Ja Jeong; Ho-Jeong Na; Seung-Heon Hong; Hyung-Min Kim
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

6.  Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent.

Authors:  Martin Mempel; Verena Voelcker; Gabriele Köllisch; Christian Plank; Roland Rad; Markus Gerhard; Christina Schnopp; Peter Fraunberger; Autar K Walli; Johannes Ring; Dietrich Abeck; Markus Ollert
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

7.  Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling.

Authors:  Alexandra Aicher; Winfried Brenner; Maaz Zuhayra; Cornel Badorff; Schirin Massoudi; Birgit Assmus; Thomas Eckey; Eberhard Henze; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

8.  Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha.

Authors:  S E Haynesworth; M A Baber; A I Caplan
Journal:  J Cell Physiol       Date:  1996-03       Impact factor: 6.384

Review 9.  Signaling danger: toll-like receptors and their potential roles in kidney disease.

Authors:  Hans-Joachim Anders; Bernhard Banas; Detlef Schlöndorff
Journal:  J Am Soc Nephrol       Date:  2004-04       Impact factor: 10.121

10.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems.

Authors:  Anna M Lundberg; Stefan K Drexler; Claudia Monaco; Lynn M Williams; Sandra M Sacre; Marc Feldmann; Brian M Foxwell
Journal:  Blood       Date:  2007-07-27       Impact factor: 22.113

View more
  160 in total

1.  Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

Authors:  Jeffery J Auletta; Robert J Deans; Amelia M Bartholomew
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

Review 2.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 3.  Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells.

Authors:  Chao Shi
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

4.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

Review 5.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 6.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

7.  Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells.

Authors:  Andrea Gray; Rene S Schloss; Martin Yarmush
Journal:  Technology (Singap World Sci)       Date:  2016-09

8.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 9.  Mesenchymal Stem Cell-Macrophage Choreography Supporting Spinal Cord Repair.

Authors:  Inés Maldonado-Lasunción; Joost Verhaagen; Martin Oudega
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 10.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.